All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
GvHD prophylaxis with donor lymphocyte infusion in patients treated with PTCy
|
A multicenter retrospective cohort study assessed the safety and efficacy of DLI in 162 patients treated with PTCy and transplanted between 2015 and 2022 within the Center for Immuno-Oncology at the National Cancer Institute.1 A total of 21 patients received ≥1 DLI after 22 PTCy-based transplants. Results were published in Bone Marrow Transplantationby Shanmugasundaram et al.1 |
| Key learnings |
| Low incidences of aGvHD (7.8%), CRS (7.8%), and cGvHD (2.6%) were observed in patients who received DLI, all of whom underwent serotherapy-containing pre-HCT conditioning. |
| The CR rate with DLI was low overall (18.4%), and in patients with disease relapse (11%) and mixed chimerism or delayed engraftment (15%). |
| The CR rate was higher in patients who received serotherapy conditioning pre-transplant vs those who did not (30% vs 4.3%). |
| Although DLI was safe and lowered the risk of GvHD in patients treated with PTCy, it demonstrated limited efficacy in preventing disease relapse or achieving long-term disease control. Further research to identify strategies to enhance the efficacy of DLI is needed. |
Abbreviations: aGvHD, acute GvHD; cGvHD, chronic GvHD; CR, complete response; CRS, cytokine release syndrome; DLI, donor lymphocyte infusion; GvHD, graft-versus-host disease; PTCy, post-transplant cyclophosphamide.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
